HCM
AMED

Highbridge Capital Management’s Amedisys AMED Stock Holding History

Highbridge Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-338,364
Closed -$33.3M – 311
2025
Q2 		$33.3M Buy
338,364
+10,089
+3% +$955K 1.36% 22
2025
Q1 		$30.4M Sell
328,275
-52,848
-14% -$4.87M 1.23% 27
2024
Q4 		$34.6M Buy
381,123
+58,223
+18% +$5.35M 1.3% 28
2024
Q3 		$31.2M Sell
322,900
-300
-0.1% -$29.3K 1.01% 33
2024
Q2 		$29.7M Buy
323,200
+83,200
+35% +$7.72M 0.95% 33
2024
Q1 		$22.1M Buy
240,000
+14,944
+7% +$1.4M 0.81% 39
2023
Q4 		$21.4M Buy
225,056
+155,056
+222% +$14.5M 0.87% 34
2023
Q3 		$6.54M Buy
+70,000
New +$6.47M 0.27% 68
2015
Q4 		– Sell
-39,864
Closed -$1.51M – 1471
2015
Q3 		$1.51M Buy
+39,864
New +$1.68M 0.02% 633

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highbridge Capital Management's AMED Position: Q3 2025 in Review

Highbridge Capital Management sold out of Amedisys (AMED) in Q3 2025, closing a stake of 338,364 shares — an estimated $33.3M sold.

Highbridge Capital Management first reported a position in AMED in Q3 2015 and held it in 9 quarters. The position peaked at $34.6M in Q4 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Highbridge Capital Management reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 338,364 Amedisys shares in Q3 2025, an estimated $33.3M.
  • Highbridge Capital Management first reported a position in Amedisys in Q3 2015 and held it in 9 quarters.
  • Highbridge Capital Management's Amedisys position peaked at $34.6M in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Highbridge Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.